Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AnaptysBio Inc ANAB

Healthcare Biotechnology
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032... see more

Recent & Breaking News (NDAQ:ANAB)

AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results

GlobeNewswire November 6, 2017

AnaptysBio to Participate in Upcoming Investor Conferences

GlobeNewswire October 31, 2017

AnaptysBio Announces Pricing of Public Offering

GlobeNewswire October 12, 2017

AnaptysBio Files Registration Statement for Proposed Public Offering

GlobeNewswire October 10, 2017

AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis

GlobeNewswire October 10, 2017

AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors

GlobeNewswire August 24, 2017

AnaptysBio to Present at Wedbush PacGrow Healthcare Conference

GlobeNewswire August 8, 2017

AnaptysBio to Participate in Upcoming Investor Conferences

GlobeNewswire June 1, 2017

AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update

GlobeNewswire May 11, 2017

AnaptysBio Announces First-In-Human Dosing of ANB019

GlobeNewswire April 6, 2017

AnaptysBio Announces 2016 Operating Results and Pipeline Progress

GlobeNewswire March 8, 2017

AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting

GlobeNewswire March 4, 2017

AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings

GlobeNewswire February 13, 2017

AnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire January 31, 2017

AnaptysBio Announces Pricing of Initial Public Offering

GlobeNewswire January 25, 2017